Dave & Buster's Price Targets Cut, September 15 2026
More than forty companies drew analyst notes before Tuesday’s open. Four of those notes landed on Dave & Buster’s, one on Nike and one on ResMed.
Dave & Buster’s Price Targets After Second Quarter Results
Dave & Buster’s runs arcades attached to restaurants, 250 of them company-owned. The brands are Dave & Buster’s and Main Event. Six of those stores opened in the second quarter, and management plans eight remodels across fiscal 2026. The company carries a market cap of $256.39 million. Revenue for the quarter came to $544.1 million. That is 2.4 percent lower than a year earlier.
Comparable store sales came in 2.9 percent below the year-earlier figure. The net loss was $12.5 million, or 36 cents a share. Adjusted EBITDA reached $98.9 million. Analysts had looked for revenue nearer $557 million, and earnings missed by 46 cents a share.
Chief executive Darin Harper spoke in Monday evening’s results release. He said the company is “laser focused on returning to same-store sales and EBITDA growth, sharpening our margin management with cost saving initiatives”.
Dave & Buster’s Stock Price Target News
Jordan Bender of Citizens reiterated Market Perform on Dave & Buster’s at 4:37 a.m. ET, the first of the four notes.
Dennis Geiger of UBS cut his target from $12 to $9 at 6:26 a.m. ET.
Mike Hickey of StoneX reiterated Hold at 7:29 a.m. ET.
Lynne Collier of Freedom Capital Markets cut her target from $13 to $9 at 7:54 a.m. ET and kept Hold.
Both new numbers sit at $9, under the $12 AnaChart records as the lowest target on the stock going into Tuesday. The four notes landed inside three hours and seventeen minutes.
What the Dave & Buster’s Board Looks Like
AnaChart records 6 analysts on Dave & Buster’s over the last twelve months. Going into Tuesday their targets ran from $12 to $28, averaging $18.33. On this stock 70.82% of targets were reached, over 425.33 days on average.
Geiger has reached 9 of the 11 targets he set on the name, at an average potential upside of 3.90%. Those targets take 29 days each.
Collier carries a met ratio of 74.9% across her whole coverage, at an average potential upside of 21.74%. Her targets take 314 days.
Hickey sits at 61.44% across 1,098 targets on 38 stocks, at an average potential upside of 26.38%, over 238 days.
Bender has reached 39.24% of his targets. His average potential upside is 24.28%, and his targets take 170 days.
Nike Target Trimmed at Telsey
Nike sells athletic footwear and apparel, and carries a market cap of $54.67 billion. Footwear supplies roughly two thirds of sales, across basketball, running and soccer lines. The company also sells under the Jordan label. Fiscal 2026 revenue held flat at $46.4 billion. On a currency-neutral basis it was 2 percent lower. The year ended on 31 May.
Diluted earnings came to $2.10 a share for the year, 3 percent below the year before. Gross margin was 42.9 percent. NIKE Direct brought in $17.7 billion, 6 percent lower than a year earlier, while wholesale took $27.5 billion, 6 percent higher. Fourth quarter revenue was $11.0 billion.
President and chief executive Elliott Hill commented on the fiscal 2026 results. He said Nike still faces top-line headwinds and that the company is “focused on consistent execution, improved profitability and scaling our wins”.
Nike Stock Price Target News
Cristina Fernandez of Telsey trimmed her target on Nike from $47 to $44 on Tuesday morning and kept Market Perform.
What the Nike Board Looks Like
AnaChart records 27 analysts on Nike over the last twelve months. Their targets run from $23 to $115, averaging $53.29. On this stock 52.85% of targets were reached, over 227.71 days on average.
Fernandez has reached 63.13% of the 601 targets she has set across 15 stocks, at an average potential upside of 39.12%. Her targets take 225 days.
ResMed Upgraded at RBC Capital
ResMed builds the machines and masks used to treat sleep apnea, and carries a market cap of $33.03 billion. Fiscal 2026 revenue reached $5.653 billion, 10 percent more than the year before. Sleep and Breathing Health supplied $4.978 billion of that. Residential Care Software accounted for $676 million. The two do not quite sum to the total, down to rounding. The company has agreed to sell its MatrixCare arm out of the software unit. That sale is expected to close in the first quarter of fiscal 2027.
Non-GAAP diluted earnings came to $11.17 a share, 17 percent above the prior year. Non-GAAP gross margin widened 240 basis points, to 62.4 percent. Fourth quarter revenue was $1.464 billion. The year ended on 30 June.
Chairman and chief executive Mick Farrell spoke in the fiscal 2026 results release. He said the year’s “$1.6 billion in free cash flow” paid for investment in innovation. The company returned more than $1 billion to shareholders.
ResMed Stock Price Target News
Craig Wong-Pan of RBC Capital upgraded ResMed from Sector Perform to Outperform on Tuesday. He lifted his target to $262 from $244.
What the ResMed Board Looks Like
AnaChart records 11 analysts on ResMed over the last twelve months. Their targets run from $215 to $321, averaging $254.45. On this stock 75.58% of targets were reached, over 191.22 days on average.
All 64 of the targets and ratings AnaChart holds for Wong-Pan sit on this one stock. He has reached 80% of his targets on it, at an average potential upside of 22.24%. Those targets take 292 days.
Questions Readers Ask About These Numbers
How do Tuesday’s two Dave & Buster’s targets compare with the recorded range? Both came in at $9, under the $12 that was the lowest AnaChart held on the name.
How should the day counts above be read? Geiger’s 29 days covers his Dave & Buster’s targets alone. Collier’s 314, Hickey’s 238 and Bender’s 170 span every stock they follow.
Where does the new ResMed target sit on its board? Wong-Pan’s $262 is above the $254.45 average AnaChart records and below the $321 high.
Every price target above is scored the same way across 9,600 tickers, reached or not reached. The full file is available at the AnaChart store.
Monday’s actions are in the 14 September update.
